Big pharmas and biotechs alike are rushing to develop weight loss therapies. Eli Lilly's blockbuster products are likely to remain profitable and relevant.

Mounjaro has become a leading GLP-1 product and could drive years of growth at Eli Lilly. The company has a great product portfolio and pipeline.

Eli Lilly and Regeneron are among the world's leading drugmakers. Both stocks have performed exceptionally well in recent years.

Eli Lilly (LLY) shares dropped more than 4% on Thursday, continuing a hasty retreat from their record high earlier this month, as investors assessed the possible impact of a promising new weight-lo...

Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of ...

A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.

Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candi...

Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in t...

While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning a...

Many top companies have announced stock splits this year after their shares surged in recent times. These operations lower the price of each individual share, making the stock more accessible for a...

Eli Lilly stock has soared, but investment bank analysts who follow the drugmaker think it can climb higher. According to electronic health records, Eli Lilly's drug for chronic weight management i...

Researchers compared the effectiveness of Novo Nordisk and Eli Lilly's weight loss drugs. Patients stopped treatment with both at high rates.

The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease. Despite the news, shares of Eli Lilly didn't take off.